Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay

Executive Summary

The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.

Advertisement

Related Content

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
Daiichi Sankyo Seals Speedier Europe Review For Quizartinib
CLL Sector Heats Up, AbbVie/Roche Upbeat About First-Line Venetoclax Combo
Pfizer Expands In Breast Cancer With Talazoparib Approval
First Approval Globally For Gilteritinib, In Japan For AML
Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Pfizer's Mylotarg Finally Gets CHMP Nod But No New Indication For Sutent
After MURANO: Roche/AbbVie Map Venclexta's Expansion Past CLL
Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement
Novartis' Rydapt: Two Indications, Two Prices

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel